This HTML5 document contains 226 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n12http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n15http://linked.opendata.cz/resource/mesh/concept/
n6http://linked.opendata.cz/resource/drugbank/company/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00927/identifier/chemspider/
n16http://linked.opendata.cz/resource/drugbank/dosage/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00927/identifier/chebi/
n19http://www.drugs.com/
n18http://bio2rdf.org/drugbank:
n27http://linked.opendata.cz/resource/drugbank/drug/DB00927/identifier/pharmgkb/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00927/identifier/wikipedia/
admshttp://www.w3.org/ns/adms#
n10http://www.rxlist.com/cgi/generic/
n29http://linked.opendata.cz/resource/drugbank/drug/DB00927/identifier/pubchem-compound/
n7http://linked.opendata.cz/resource/drugbank/patent/
n20http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n4http://linked.opendata.cz/resource/drugbank/medicinal-product/
n14http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n30http://linked.opendata.cz/resource/drugbank/drug/DB00927/identifier/pubchem-substance/
n28http://linked.opendata.cz/resource/drugbank/drug/DB00927/identifier/kegg-drug/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00927/identifier/drugbank/
n5http://linked.opendata.cz/resource/drugbank/property/
n9http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
xsdhhttp://www.w3.org/2001/XMLSchema#
n26http://linked.opendata.cz/resource/drugbank/drug/DB00927/identifier/national-drug-code-directory/
n31http://linked.opendata.cz/resource/atc/
n11http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00927
rdf:type
n3:Drug
n3:description
A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion. [PubChem]
n3:dosage
n16:271B62C1-363D-11E5-9242-09173F13E4C5 n16:271B62C2-363D-11E5-9242-09173F13E4C5 n16:271B62C3-363D-11E5-9242-09173F13E4C5 n16:271B62C4-363D-11E5-9242-09173F13E4C5 n16:271B62BE-363D-11E5-9242-09173F13E4C5 n16:271B62BF-363D-11E5-9242-09173F13E4C5 n16:271B62C0-363D-11E5-9242-09173F13E4C5 n16:271B62C5-363D-11E5-9242-09173F13E4C5 n16:271B62C7-363D-11E5-9242-09173F13E4C5 n16:271B62BA-363D-11E5-9242-09173F13E4C5 n16:271B62BB-363D-11E5-9242-09173F13E4C5 n16:271B62BC-363D-11E5-9242-09173F13E4C5 n16:271B62BD-363D-11E5-9242-09173F13E4C5 n16:271B62C6-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
2.5-3.5 hours
n3:indication
For the treatment of peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD).
n3:manufacturer
n6:271B6273-363D-11E5-9242-09173F13E4C5 n6:271B6274-363D-11E5-9242-09173F13E4C5 n6:271B6271-363D-11E5-9242-09173F13E4C5 n6:271B6272-363D-11E5-9242-09173F13E4C5 n6:271B6283-363D-11E5-9242-09173F13E4C5 n6:271B6275-363D-11E5-9242-09173F13E4C5 n6:271B6276-363D-11E5-9242-09173F13E4C5 n6:271B627D-363D-11E5-9242-09173F13E4C5 n6:271B6280-363D-11E5-9242-09173F13E4C5 n6:271B6281-363D-11E5-9242-09173F13E4C5 n6:271B627E-363D-11E5-9242-09173F13E4C5 n6:271B626F-363D-11E5-9242-09173F13E4C5 n6:271B627F-363D-11E5-9242-09173F13E4C5 n6:271B6270-363D-11E5-9242-09173F13E4C5 n6:271B626D-363D-11E5-9242-09173F13E4C5 n6:271B626E-363D-11E5-9242-09173F13E4C5 n6:271B6277-363D-11E5-9242-09173F13E4C5 n6:271B627B-363D-11E5-9242-09173F13E4C5 n6:271B6285-363D-11E5-9242-09173F13E4C5 n6:271B6286-363D-11E5-9242-09173F13E4C5 n6:271B6282-363D-11E5-9242-09173F13E4C5 n6:271B6284-363D-11E5-9242-09173F13E4C5 n6:271B6289-363D-11E5-9242-09173F13E4C5 n6:271B628A-363D-11E5-9242-09173F13E4C5 n6:271B6287-363D-11E5-9242-09173F13E4C5 n6:271B6288-363D-11E5-9242-09173F13E4C5 n6:271B627A-363D-11E5-9242-09173F13E4C5 n6:271B628D-363D-11E5-9242-09173F13E4C5 n6:271B627C-363D-11E5-9242-09173F13E4C5 n6:271B628E-363D-11E5-9242-09173F13E4C5 n6:271B6278-363D-11E5-9242-09173F13E4C5 n6:271B628B-363D-11E5-9242-09173F13E4C5 n6:271B6279-363D-11E5-9242-09173F13E4C5 n6:271B628C-363D-11E5-9242-09173F13E4C5
owl:sameAs
n18:DB00927 n20:DB00927
dcterms:title
Famotidine
adms:identifier
n22:Famotidine n23:3208 n24:DB00927 n25:4975 n26:0006-3537-50 n27:PA449586 n28:D00318 n29:5702160 n30:46507397
n3:mechanismOfAction
Famotidine binds competitively to H<sub>2</sub>-receptors located on the basolateral membrane of the parietal cell, blocking histamine affects. This competitive inhibition results in reduced basal and nocturnal gastric acid secretion and a reduction in gastric volume, acidity, and amount of gastric acid released in response to stimuli including food, caffeine, insulin, betazole, or pentagastrin.
n3:packager
n6:271B623F-363D-11E5-9242-09173F13E4C5 n6:271B6240-363D-11E5-9242-09173F13E4C5 n6:271B624F-363D-11E5-9242-09173F13E4C5 n6:271B6250-363D-11E5-9242-09173F13E4C5 n6:271B624D-363D-11E5-9242-09173F13E4C5 n6:271B624E-363D-11E5-9242-09173F13E4C5 n6:271B624B-363D-11E5-9242-09173F13E4C5 n6:271B624C-363D-11E5-9242-09173F13E4C5 n6:271B6249-363D-11E5-9242-09173F13E4C5 n6:271B624A-363D-11E5-9242-09173F13E4C5 n6:271B6247-363D-11E5-9242-09173F13E4C5 n6:271B6248-363D-11E5-9242-09173F13E4C5 n6:271B6245-363D-11E5-9242-09173F13E4C5 n6:271B6246-363D-11E5-9242-09173F13E4C5 n6:271B6243-363D-11E5-9242-09173F13E4C5 n6:271B6244-363D-11E5-9242-09173F13E4C5 n6:271B6241-363D-11E5-9242-09173F13E4C5 n6:271B6242-363D-11E5-9242-09173F13E4C5 n6:271B625F-363D-11E5-9242-09173F13E4C5 n6:271B6260-363D-11E5-9242-09173F13E4C5 n6:271B625D-363D-11E5-9242-09173F13E4C5 n6:271B625E-363D-11E5-9242-09173F13E4C5 n6:271B625B-363D-11E5-9242-09173F13E4C5 n6:271B625C-363D-11E5-9242-09173F13E4C5 n6:271B6259-363D-11E5-9242-09173F13E4C5 n6:271B625A-363D-11E5-9242-09173F13E4C5 n6:271B6257-363D-11E5-9242-09173F13E4C5 n6:271B6258-363D-11E5-9242-09173F13E4C5 n6:271B6255-363D-11E5-9242-09173F13E4C5 n6:271B6256-363D-11E5-9242-09173F13E4C5 n6:271B6253-363D-11E5-9242-09173F13E4C5 n6:271B6254-363D-11E5-9242-09173F13E4C5 n6:271B6251-363D-11E5-9242-09173F13E4C5 n6:271B6252-363D-11E5-9242-09173F13E4C5 n6:271B623E-363D-11E5-9242-09173F13E4C5 n6:271B626B-363D-11E5-9242-09173F13E4C5 n6:271B626C-363D-11E5-9242-09173F13E4C5 n6:271B623C-363D-11E5-9242-09173F13E4C5 n6:271B6269-363D-11E5-9242-09173F13E4C5 n6:271B623D-363D-11E5-9242-09173F13E4C5 n6:271B626A-363D-11E5-9242-09173F13E4C5 n6:271B623A-363D-11E5-9242-09173F13E4C5 n6:271B6267-363D-11E5-9242-09173F13E4C5 n6:271B623B-363D-11E5-9242-09173F13E4C5 n6:271B6268-363D-11E5-9242-09173F13E4C5 n6:271B6238-363D-11E5-9242-09173F13E4C5 n6:271B6265-363D-11E5-9242-09173F13E4C5 n6:271B6239-363D-11E5-9242-09173F13E4C5 n6:271B6266-363D-11E5-9242-09173F13E4C5 n6:271B6236-363D-11E5-9242-09173F13E4C5 n6:271B6263-363D-11E5-9242-09173F13E4C5 n6:271B6237-363D-11E5-9242-09173F13E4C5 n6:271B6264-363D-11E5-9242-09173F13E4C5 n6:271B6234-363D-11E5-9242-09173F13E4C5 n6:271B6261-363D-11E5-9242-09173F13E4C5 n6:271B6235-363D-11E5-9242-09173F13E4C5 n6:271B6262-363D-11E5-9242-09173F13E4C5 n6:271B6232-363D-11E5-9242-09173F13E4C5 n6:271B6233-363D-11E5-9242-09173F13E4C5
n3:patent
n7:5075114 n7:6814978 n7:2178277 n7:2052679
n3:routeOfElimination
Renal clearance is 250-450 mL/min, indicating some tubular excretion.
n3:synonym
3-(((2-((Aminoiminomethyl)amino)-4-thiazolyl)methyl)thio)-N-(aminosulfonyl)propanimidamide 3-(((2-((Diaminomethylene)amino)-4-thiazolyl)methyl)thio)-N(sup 2)-sulfamoylpropionamidine (1-Amino-3-(((2-((diaminomethylene)amino)-4-thiazolyl)methyl)thio)propylidene)sulfamide Famotidina Pepcid Famotidinum N-Sulfamoyl-3-((2-guanidinothiazol-4-yl)methylthio)propionamide
n3:toxicity
Intravenous, mouse: LD<sub>50</sub> = 244.4mg/kg; Oral, mouse: LD<sub>50</sub> = 4686 mg/kg. Symptoms of overdose include emesis, restlessness, pallor of mucous membranes or redness of mouth and ears, hypotension, tachycardia and collapse.
n11:hasAHFSCode
n12:56-28-12
n3:foodInteraction
Limit caffeine intake. Take without regard to meals, food may slightly increase the product's bioavailability. Avoid alcohol.
n3:proteinBinding
15-20%
n3:synthesisReference
Montserrat Ballester-Rodes, Francisco E. Palomo-Nicolau, Antonio L. Palomo-Coli, "Famotidine polymorphic forms and their preparation process." U.S. Patent US5021582, issued March, 1987.
n14:hasConcept
n15:M0024121
foaf:page
n9:pep1325.shtml n10:famot.htm n19:famotidine.html
n3:IUPAC-Name
n5:271B62CC-363D-11E5-9242-09173F13E4C5
n3:InChI
n5:271B62D2-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n5:271B62D1-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n5:271B62CE-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n5:271B62CF-363D-11E5-9242-09173F13E4C5
n3:SMILES
n5:271B62D0-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n5:271B62CA-363D-11E5-9242-09173F13E4C5 n5:271B62E2-363D-11E5-9242-09173F13E4C5
n3:logP
n5:271B62CB-363D-11E5-9242-09173F13E4C5 n5:271B62C8-363D-11E5-9242-09173F13E4C5 n5:271B62E4-363D-11E5-9242-09173F13E4C5
n3:logS
n5:271B62C9-363D-11E5-9242-09173F13E4C5
n11:hasATCCode
n31:A02BA03
n3:H-Bond-Acceptor-Count
n5:271B62D8-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n5:271B62D9-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n5:271B62D3-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n5:271B62D4-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n5:271B62D6-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n5:271B62D5-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n5:271B62D7-363D-11E5-9242-09173F13E4C5
n3:absorption
The bioavailability of oral doses is 40-45%.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
76824-35-6
n3:category
n3:clearance
* renal cl=250-450 mL/min
n3:containedIn
n4:271B62A0-363D-11E5-9242-09173F13E4C5 n4:271B62A1-363D-11E5-9242-09173F13E4C5 n4:271B629E-363D-11E5-9242-09173F13E4C5 n4:271B629F-363D-11E5-9242-09173F13E4C5 n4:271B629C-363D-11E5-9242-09173F13E4C5 n4:271B629D-363D-11E5-9242-09173F13E4C5 n4:271B62AC-363D-11E5-9242-09173F13E4C5 n4:271B62AD-363D-11E5-9242-09173F13E4C5 n4:271B62AA-363D-11E5-9242-09173F13E4C5 n4:271B62AB-363D-11E5-9242-09173F13E4C5 n4:271B62A8-363D-11E5-9242-09173F13E4C5 n4:271B62A9-363D-11E5-9242-09173F13E4C5 n4:271B62B2-363D-11E5-9242-09173F13E4C5 n4:271B62A6-363D-11E5-9242-09173F13E4C5 n4:271B62A7-363D-11E5-9242-09173F13E4C5 n4:271B62B3-363D-11E5-9242-09173F13E4C5 n4:271B6293-363D-11E5-9242-09173F13E4C5 n4:271B62A5-363D-11E5-9242-09173F13E4C5 n4:271B6290-363D-11E5-9242-09173F13E4C5 n4:271B6291-363D-11E5-9242-09173F13E4C5 n4:271B628F-363D-11E5-9242-09173F13E4C5 n4:271B62B8-363D-11E5-9242-09173F13E4C5 n4:271B62B9-363D-11E5-9242-09173F13E4C5 n4:271B62B6-363D-11E5-9242-09173F13E4C5 n4:271B62B7-363D-11E5-9242-09173F13E4C5 n4:271B62B4-363D-11E5-9242-09173F13E4C5 n4:271B62B5-363D-11E5-9242-09173F13E4C5 n4:271B62B0-363D-11E5-9242-09173F13E4C5 n4:271B62B1-363D-11E5-9242-09173F13E4C5 n4:271B62AE-363D-11E5-9242-09173F13E4C5 n4:271B62AF-363D-11E5-9242-09173F13E4C5 n4:271B629A-363D-11E5-9242-09173F13E4C5 n4:271B629B-363D-11E5-9242-09173F13E4C5 n4:271B6298-363D-11E5-9242-09173F13E4C5 n4:271B6299-363D-11E5-9242-09173F13E4C5 n4:271B6295-363D-11E5-9242-09173F13E4C5 n4:271B6296-363D-11E5-9242-09173F13E4C5 n4:271B6294-363D-11E5-9242-09173F13E4C5 n4:271B6292-363D-11E5-9242-09173F13E4C5 n4:271B6297-363D-11E5-9242-09173F13E4C5 n4:271B62A4-363D-11E5-9242-09173F13E4C5 n4:271B62A2-363D-11E5-9242-09173F13E4C5 n4:271B62A3-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n5:271B62DE-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n5:271B62E0-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n5:271B62E1-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n5:271B62E3-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n5:271B62DD-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n5:271B62DC-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n5:271B62DF-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n5:271B62CD-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n5:271B62DA-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n5:271B62DB-363D-11E5-9242-09173F13E4C5